Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain EXEL message board posts where the ticker symbol EXEL has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest EXEL SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-17-000195 Size: 6 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-17-000194 Size: 6 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-17-000193 Size: 9 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-17-000192 Size: 6 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-17-000191 Size: 6 KB
2017-11-17
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-17-000190 Size: 7 KB
2017-11-17
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-17-009717 (34 Act)  Size: 11 KB
2017-11-07 000-30235
171181334
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0000939767-17-000183 (34 Act)  Size: 8 MB
2017-11-01 000-30235
171169139
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0000939767-17-000182 (34 Act)  Size: 326 KB
2017-11-01 000-30235
171169082
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000939767-17-000172 Size: 9 KB
2017-10-05
More EXEL SEC Filings


Related news from
Fri, 15 Dec 2017
13:02:16 +0000
Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 15, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Exelixis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more <b>(Read more...)</b>
Tue, 12 Dec 2017
16:12:10 +0000
Why Exelixis, Inc. Stock Is Bound to Soar Higher in the Long Run
The former is used in combination with Roche’s Zelboraf as a treatment for advanced melanoma. Also, EXEL stock holders are looking at first-line approval for Cabometyx for hepatocellular carcinoma (a type of liver cancer) as potential for significant upside. EXEL retains marketing rights for Cabometyx in the U.S. and it has licensed marketing rights to Takeda Pharmaceutical Co Ltd (ADR) (OTCMKTS:TKPYY) in Japan and France-based Ipsen S A/S ADR (OTCMKTS:IPSEY) outside the U.S. and Japan.
Tue, 12 Dec 2017
14:31:00 +0000
3 Top Healthcare Stocks to Buy in December
Now could be the perfect time to add to your portfolio healthcare stocks that can benefit from aging baby boomers and regulatory approvals.
Fri, 08 Dec 2017
13:04:24 +0000
See what the IHS Markit Score report has to say about Exelixis Inc.
Exelixis Inc NASDAQ/NGS:EXEL
Thu, 07 Dec 2017
14:11:00 +0000
Is Exelixis, Inc. a Buy?
This biotech stock is up close to 80% in 2017. But can Exelixis go even higher?
Wed, 06 Dec 2017
21:50:00 +0000
Top 5 Biotech Stocks for 2017
Biotech can be risky, but these top biotech stocks have stable track records.
Mon, 04 Dec 2017
18:45:02 +0000
Analysts’ Recommendations for Regeneron
In October 2017, Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that their Phase 3 dupilumab study had met its primary and secondary endpoints. The study was conducted to evaluate the safety ...
Fri, 01 Dec 2017
08:00:00 +0000
Stocks To Watch: Exelixis Sees Relative Strength Rating Rise To 84
Exelixis shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.
Mon, 27 Nov 2017
13:15:00 +0000
Report: Developing Opportunities within PayPal, Exelixis, International Business Machines, Opko Health, Envision Healthcare, and Zynga — Future Expectations, Projections Moving into 2018
NEW YORK, Nov. 27, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PayPal ...
Mon, 27 Nov 2017
12:50:00 +0000
Blog Exposure - Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma
Stock Monitor: Syros Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / November 27, 2017 / Active-Investors issued a free report on Exelixis, Inc. (NASDAQ: EXEL ), which is readily accessible upon ...
Sat, 25 Nov 2017
16:02:22 +0000
Best Growth Stocks To Buy
High-growth stocks that are financially stable are attractive for many reasons. They provide a strong upside to your portfolio, with less likelihood of downside risks compared to less financially robustRead More...
Thu, 23 Nov 2017
12:31:52 +0000
Gauging Exelixis’s High Hopes for Cotellic
On November 10, 2015, the FDA approved Exelixis’s (EXEL) Cotellic in combination with Roche Holdings’ (RHHBY) Zelboraf (vemurafenib) as a treatment option.
Wed, 22 Nov 2017
15:32:37 +0000
Inside Exelixis’s Label Expansion Collaborations for Cabozantinib
As a part of the broader lifecycle management for Cabometyx, Exelixis is exploring the drug in combination with other immune checkpoint inhibitors.
Wed, 22 Nov 2017
14:03:01 +0000
What Else Could Boost Exelixis’s Future Revenues?
On October 16, Exelixis and Ipsen announced that Cabometyx (cabozaninib) met its primary endpoint of OS (overall survival) in the phase-3 Celestial trial.
Wed, 22 Nov 2017
12:33:25 +0000
Behind Exelixis’s Cabometyx Strategy for 2018
Exelixis (EXEL) expects the FDA's approval for Cabometyx for first-line RCC (renal cell carcinoma) to be a major revenue driver.
Tue, 21 Nov 2017
21:45:00 +0000
Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations
Exelixis, Inc. today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the
Tue, 21 Nov 2017
21:30:00 +0000
Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium
Exelixis, Inc. today announced that the phase 3 CELESTIAL trial results have been accepted as a late-breaking presentation at the 2018 ASCO-GI Symposium, which is being held January 18–20, 2018 in San Francisco.
Tue, 21 Nov 2017
19:55:10 +0000
Reading the Expectations for Exelixis’s Net Profit Margin in 2017
In 3Q17, Exelixis (EXEL) witnessed the rapid adoption of Cabometyx, mainly driven by the company’s promotional efforts focused on community oncologists.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This site is a gem, and based on the posts by many members and my personal experience it is a site for learning, sharing and especially making money." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards